Helix BioPharma Closes Private Placement

- June 8th, 2018

Helix BioPharma (TSX:HBP) an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD940,800. As quoted in the press release: The terms of the placement are for the purchase of units at $1.20 per unit. Each unit is …

Helix BioPharma (TSX:HBP) an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD940,800.

As quoted in the press release:

The terms of the placement are for the purchase of units at $1.20 per unit. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $1.50 and have an expiry of five years from the date of issuance.  Helix intends to use the net proceeds of the private placement for working capital and research and development activities.

ACM Alpha Management Consulting Est. provided financial advisory services to Helix in connection with the private placement.

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply